Article Information
History
- May 17, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Hiroshi Mukaea,
- Hiroshi Yotsuyanagib,
- Norio Ohmagaric,
- Yohei Doid,e,
- Takumi Imamuraf,
- Takuhiro Sonoyamaf,
- Takahiro Fukuharaf,
- Genki Ichihashif,
- Takao Sanakig,
- Keiko Babag,
- Yosuke Takedaf,
- Yuko Tsugef and
- Takeki Ueharaf,*
- aDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- bThe Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- cDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
- dDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- eDepartments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan
- fDrug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
- gPharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
- ↵*Corresponding author:
Takeki Uehara, Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Address: 8F, Nissay Yodoyabashi East, 3-3-13 Imabashi, Chuo-ku, Osaka 541-0042, Japan, Email: takeki.uehara{at}shionogi.co.jp, Telephone: +81-6-6209-6907
Posted May 17, 2022.
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
